|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC25A33 |
Gene summary for SLC25A33 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC25A33 | Gene ID | 84275 |
| Gene name | solute carrier family 25 member 33 | |
| Gene Alias | BMSC-MCP | |
| Cytomap | 1p36.22 | |
| Gene Type | protein-coding | GO ID | GO:0000002 | UniProtAcc | Q9BSK2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84275 | SLC25A33 | LZE20T | Human | Esophagus | ESCC | 8.45e-09 | 1.54e-01 | 0.0662 |
| 84275 | SLC25A33 | LZE24T | Human | Esophagus | ESCC | 1.33e-24 | 1.00e+00 | 0.0596 |
| 84275 | SLC25A33 | LZE21T | Human | Esophagus | ESCC | 3.20e-02 | 2.91e-01 | 0.0655 |
| 84275 | SLC25A33 | P1T-E | Human | Esophagus | ESCC | 1.54e-10 | 7.55e-01 | 0.0875 |
| 84275 | SLC25A33 | P2T-E | Human | Esophagus | ESCC | 2.77e-63 | 1.12e+00 | 0.1177 |
| 84275 | SLC25A33 | P4T-E | Human | Esophagus | ESCC | 4.05e-40 | 1.21e+00 | 0.1323 |
| 84275 | SLC25A33 | P5T-E | Human | Esophagus | ESCC | 5.33e-37 | 8.80e-01 | 0.1327 |
| 84275 | SLC25A33 | P8T-E | Human | Esophagus | ESCC | 1.61e-20 | 4.26e-01 | 0.0889 |
| 84275 | SLC25A33 | P9T-E | Human | Esophagus | ESCC | 7.49e-17 | 4.82e-01 | 0.1131 |
| 84275 | SLC25A33 | P10T-E | Human | Esophagus | ESCC | 3.18e-48 | 9.15e-01 | 0.116 |
| 84275 | SLC25A33 | P11T-E | Human | Esophagus | ESCC | 2.05e-14 | 9.69e-01 | 0.1426 |
| 84275 | SLC25A33 | P12T-E | Human | Esophagus | ESCC | 2.63e-47 | 9.88e-01 | 0.1122 |
| 84275 | SLC25A33 | P15T-E | Human | Esophagus | ESCC | 1.58e-31 | 8.31e-01 | 0.1149 |
| 84275 | SLC25A33 | P16T-E | Human | Esophagus | ESCC | 7.27e-34 | 5.80e-01 | 0.1153 |
| 84275 | SLC25A33 | P17T-E | Human | Esophagus | ESCC | 2.88e-05 | 3.31e-01 | 0.1278 |
| 84275 | SLC25A33 | P19T-E | Human | Esophagus | ESCC | 3.08e-05 | 3.94e-01 | 0.1662 |
| 84275 | SLC25A33 | P20T-E | Human | Esophagus | ESCC | 5.41e-36 | 9.93e-01 | 0.1124 |
| 84275 | SLC25A33 | P21T-E | Human | Esophagus | ESCC | 7.36e-28 | 6.15e-01 | 0.1617 |
| 84275 | SLC25A33 | P22T-E | Human | Esophagus | ESCC | 3.53e-20 | 4.02e-01 | 0.1236 |
| 84275 | SLC25A33 | P23T-E | Human | Esophagus | ESCC | 2.68e-36 | 1.07e+00 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003286915 | Prostate | Tumor | cellular response to insulin stimulus | 63/3246 | 203/18723 | 1.15e-06 | 2.18e-05 | 63 |
| GO:003286815 | Prostate | Tumor | response to insulin | 75/3246 | 264/18723 | 4.94e-06 | 7.68e-05 | 75 |
| GO:004346715 | Prostate | Tumor | regulation of generation of precursor metabolites and energy | 43/3246 | 130/18723 | 9.55e-06 | 1.39e-04 | 43 |
| GO:199054217 | Prostate | Tumor | mitochondrial transmembrane transport | 36/3246 | 102/18723 | 9.84e-06 | 1.43e-04 | 36 |
| GO:003030714 | Prostate | Tumor | positive regulation of cell growth | 50/3246 | 166/18723 | 3.42e-05 | 4.01e-04 | 50 |
| GO:190357818 | Prostate | Tumor | regulation of ATP metabolic process | 30/3246 | 87/18723 | 8.61e-05 | 8.53e-04 | 30 |
| GO:007259315 | Prostate | Tumor | reactive oxygen species metabolic process | 63/3246 | 239/18723 | 2.87e-04 | 2.32e-03 | 63 |
| GO:001593113 | Prostate | Tumor | nucleobase-containing compound transport | 59/3246 | 222/18723 | 3.49e-04 | 2.75e-03 | 59 |
| GO:005188115 | Prostate | Tumor | regulation of mitochondrial membrane potential | 25/3246 | 74/18723 | 4.62e-04 | 3.47e-03 | 25 |
| GO:004592715 | Prostate | Tumor | positive regulation of growth | 66/3246 | 259/18723 | 5.73e-04 | 4.13e-03 | 66 |
| GO:001700411 | Prostate | Tumor | cytochrome complex assembly | 14/3246 | 36/18723 | 1.79e-03 | 1.05e-02 | 14 |
| GO:200037715 | Prostate | Tumor | regulation of reactive oxygen species metabolic process | 42/3246 | 157/18723 | 2.02e-03 | 1.16e-02 | 42 |
| GO:014005311 | Prostate | Tumor | mitochondrial gene expression | 31/3246 | 108/18723 | 2.31e-03 | 1.30e-02 | 31 |
| GO:190371514 | Prostate | Tumor | regulation of aerobic respiration | 12/3246 | 33/18723 | 7.03e-03 | 3.16e-02 | 12 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC25A33 | SNV | Missense_Mutation | novel | c.578C>T | p.Ser193Leu | p.S193L | Q9BSK2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC25A33 | SNV | Missense_Mutation | c.847G>C | p.Gly283Arg | p.G283R | Q9BSK2 | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-A6-5659-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SLC25A33 | SNV | Missense_Mutation | rs750582662 | c.112C>T | p.Arg38Trp | p.R38W | Q9BSK2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| SLC25A33 | insertion | Frame_Shift_Ins | novel | c.695_696insT | p.Gly235TrpfsTer10 | p.G235Wfs*10 | Q9BSK2 | protein_coding | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | ||
| SLC25A33 | SNV | Missense_Mutation | rs138525926 | c.956N>A | p.Arg319His | p.R319H | Q9BSK2 | protein_coding | tolerated(0.38) | benign(0.005) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SLC25A33 | SNV | Missense_Mutation | c.775N>G | p.Thr259Ala | p.T259A | Q9BSK2 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLC25A33 | SNV | Missense_Mutation | novel | c.641N>C | p.Leu214Pro | p.L214P | Q9BSK2 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC25A33 | SNV | Missense_Mutation | rs750582662 | c.112C>T | p.Arg38Trp | p.R38W | Q9BSK2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| SLC25A33 | SNV | Missense_Mutation | rs750582662 | c.112N>T | p.Arg38Trp | p.R38W | Q9BSK2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SLC25A33 | SNV | Missense_Mutation | c.100N>T | p.Val34Phe | p.V34F | Q9BSK2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |